Pharmacists in Cimarron, KS Accepting Medicare
4 Pharmacists found. Showing 1 - 4
 Dr. Matthew Dylan Monical, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 101 S Main St, Cimarron, KS 67835 Phone: 620-855-2242 |
Mr. James E Coast, RPH,CGP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 101 S Main, Cimarron, KS 67835 Phone: 620-855-2242 Fax: 620-855-3616 |
Dr. Christopher Allen Mick, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 202 N Main St, Cimarron, KS 67835 Phone: 620-855-2055 |
Michael Edward Coast, RPH, CGP Pharmacist - Geriatric Medicare: Not Enrolled in Medicare Practice Location: 100 West Ave A, Suite B, Cimarron, KS 67835 Phone: 620-855-0095 Fax: 620-855-3411 |
News Archive
Gastric bypass dramatically improves multiple cardiovascular risk factors in the long term
New research from the Cleveland Clinic shows most patients with diabetes and obesity who undergo gastric bypass not only experience remission of their diabetes and lose significant weight, but they also reduce their risk of having a heart attack by 40 percent and their risk for suffering a stroke by 42 percent, over a 10-year time horizon.
PLoS Neglected Tropical Diseases features Inovio's Chikungunya DNA vaccine
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper highlighting positive results from Inovio's multi-antigen Chikungunya virus (CHIKV) DNA vaccine in PLoS Neglected Tropical Diseases.
UK health communication researcher seeks solutions for disposing leftover medicine
University of Kentucky health communication researcher Don Helme is partnering with the Kentucky Attorney General's office to gauge public opinion on a new drug deactivation pouch, part of a larger effort to develop solutions to the state's opioid epidemic.
World's largest biotechnology company acquires Tularik
Amgen Inc., the world's largest biotechnology company, and Tularik Inc., a pioneer in drug discovery related to cell signaling and the control of gene expression, today jointly announced that they have signed a definitive merger agreement whereby Tularik will become a wholly-owned subsidiary of Amgen in a stock for stock transaction.
› Verified 1 days ago